Literature DB >> 17936687

Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex.

David A Muzykewicz1, Peter Newberry, Nicole Danforth, Elkan F Halpern, Elizabeth A Thiele.   

Abstract

Psychiatric symptoms were retrospectively assessed in a clinic population of 241 children and adults with tuberous sclerosis complex (TSC). Sixty-six (27%) patients had a history of mood disorder symptoms, 66 (27%) had a history of anxiety disorder symptoms, 73 (30%) had a history of attention-deficit hyperactivity disorder (ADHD) symptoms, and 68 (28%) had a history of aggressive/disruptive behavior disorder symptoms. Significant relationships were found between these symptoms and patient age, gender, genetic mutation, seizure history, surgical history, cognitive impairment, features of autism or pervasive developmental disorder, and neurological manifestations of TSC. In 43 patients seen by at least one of two affiliated psychiatrists, the most common formal diagnoses were anxiety disorders (28%), mood disorders (26%), adjustment disorders (21%), ADHD (21%), and mental disorders not otherwise specified due to general medical condition (42%). Citalopram demonstrated efficacy in treating anxiety and depression, and risperidone, in treating problematic behaviors.

Entities:  

Mesh:

Year:  2007        PMID: 17936687     DOI: 10.1016/j.yebeh.2007.07.010

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  38 in total

1.  Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy.

Authors:  X Huang; J McMahon; Y Huang
Journal:  Neuroscience       Date:  2012-04-20       Impact factor: 3.590

2.  Resting and task-modulated high-frequency brain rhythms measured by scalp encephalography in infants with tuberous sclerosis complex.

Authors:  Catherine Stamoulis; Vanessa Vogel-Farley; Geneva Degregorio; Shafali S Jeste; Charles A Nelson
Journal:  J Autism Dev Disord       Date:  2015-02

Review 3.  A clinical update on tuberous sclerosis complex-associated neuropsychiatric disorders (TAND).

Authors:  Petrus J de Vries; Lucy Wilde; Magdalena C de Vries; Romina Moavero; Deborah A Pearson; Paolo Curatolo
Journal:  Am J Med Genet C Semin Med Genet       Date:  2018-08-16       Impact factor: 3.908

4.  NitroSynapsin for the treatment of neurological manifestations of tuberous sclerosis complex in a rodent model.

Authors:  Shu-Ichi Okamoto; Olga Prikhodko; Juan Pina-Crespo; Anthony Adame; Scott R McKercher; Laurence M Brill; Nobuki Nakanishi; Chang-Ki Oh; Tomohiro Nakamura; Eliezer Masliah; Stuart A Lipton
Journal:  Neurobiol Dis       Date:  2019-03-27       Impact factor: 5.996

Review 5.  Mechanism-based treatment in tuberous sclerosis complex.

Authors:  Kristina Jülich; Mustafa Sahin
Journal:  Pediatr Neurol       Date:  2013-12-05       Impact factor: 3.372

6.  Characterizing sleep disorders of adults with tuberous sclerosis complex: a questionnaire-based study and review.

Authors:  Agnies M van Eeghen; Adam I Numis; Brigid A Staley; Samuel E Therrien; Ronald L Thibert; Elizabeth A Thiele
Journal:  Epilepsy Behav       Date:  2010-12-03       Impact factor: 2.937

Review 7.  Rapamycin for treating Tuberous sclerosis and Autism spectrum disorders.

Authors:  Dan Ehninger; Alcino J Silva
Journal:  Trends Mol Med       Date:  2010-11-04       Impact factor: 11.951

8.  Brain MR spectroscopic abnormalities in "MRI-negative" tuberous sclerosis complex patients.

Authors:  William E Wu; Ivan I Kirov; Assaf Tal; James S Babb; Sarah Milla; Joseph Oved; Howard L Weiner; Orrin Devinsky; Oded Gonen
Journal:  Epilepsy Behav       Date:  2013-03-22       Impact factor: 2.937

Review 9.  From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis.

Authors:  D Ehninger; P J de Vries; A J Silva
Journal:  J Intellect Disabil Res       Date:  2009-08-19

10.  Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex.

Authors:  Robert P Carson; Cary Fu; Peggy Winzenburger; Kevin C Ess
Journal:  Hum Mol Genet       Date:  2012-10-09       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.